| http://www.w3.org/ns/prov#value | - t venture.That is a nice early return from the joint venture, but it does underscore the likelihood that features of health care reform will start to have an impact on business development.Take, for instance, Bristol-Myers Squibb???s discussion of the importance of its relationship with Sanofi Aventis for Plavix in considering how the company will be affected in 2011, when a new 50% Part D discoun
|
